The Center for Disease Control estimated that about 86% of all US healthcare spending is on treating chronic medical conditions. On a global scale, health-risk behavior, such as physical inactivity and poor nutrition, costs healthcare systems around the world $53 billion. As the cases of chronic illnesses increases, the demand for long-term care increases and patient compliance is crucial.
As it often happens, patients who live with a certain medical condition for the rest of their lives are not complying with the health regimes required and fail to take care of themselves. The solution is an improvement of long term patient care.
Biotricity (OTCQB: BTCY) is employing innovative monitoring technology to come up with solutions for such problems. The company has two patient monitoring devices in its pipeline that have potential to disrupt the healthcare industry by providing help patients and physicians deal with a range of heart problems. Integration of remote monitoring devices into existing healthcare diagnostic and billing systems will position such solutions to resolve a number of health-related problems.
The two wireless ECG monitoring devices are bioflux and biolife. Bioflux is already submitted to the FDA, and is designed to monitor and improve a doctor’s ability to test and diagnose patients with cardiovascular problems. Biolife is designed for individuals to track their progress in real time and stay motivated while making lifestyle changes.
Bitotricity CEO, Waqass Al-Siddiq, explained, "Based on our research, it is clear that if an individual has a feedback loop, it incentivises them to follow doctor’s instructions... The only way to address the deficiencies in healthcare is to encourage disease prevention and drive up patient compliance. Patients with long-term conditions deserve better care and biotricity’s monitoring devices pave the way for a fundamentally new approach to help them lead long, healthy lives.”